Vigil Neuroscience (VIGL) IPO: VIGL is set to debut today

2 min read | January 08, 2022 06:12 AM AEDT | By Versha Jain

Google News:

Vigil Neuroscience (VIGL) IPO: VIGL is set to debut today — Image source: iQoncept,Shutterstock

Recent News

Why Are These Three ASX Shares On Bell Potter’s Radar This Month?

Can Microba’s Trading Halt Signal A Key Turning Point?

Why Is Green Technology Metals Expanding Its Share Base?

Why Are Oil Prices Casting A Shadow Over Australian Shares?

Make Kalkine Media
My Trusted Source

Highlights

Vigil Neuroscience announced the pricing of its IPO at US$14.00 per share.

Vigil is offering 7,000,000 shares of its common stocks.

It will trade on Nasdaq under the ticker symbol VIGL.

Biotechnology company Vigil Neuroscience will debut on Nasdaq Friday.

The company is offering 7,000,000 shares of its common stocks for US$14.00 per share. The initial IPO price range was US$15.00 to US$17.00 per share.

Additionally, a total of 1,050,000 shares are reserved for the underwriters who can exercise their 30-day buy option at the offering price after deducting discounts and commissions.

The gross proceeds from this offering are expected to be US$98.0 million.

Also Read: Top technology and gaming stocks to explore in 2022

The company filed the registration statement on Form S-1 for the IPO on November 19, 2021.

The Securities and Exchange Commission (SEC) gave its nod on Jan 6, 2022. The offering will close on Jan 11, 2022, subject to the completion of customary closing conditions. The stocks were expected to start trading on Nasdaq Friday, January 7, 2022, under the ticker symbol VIGL.

The joint book-running managers for the IPO are Morgan Stanley, Stifel, Jefferies, and Guggenheim Securities.

Also Read: Stocks that could give FAANG companies a run for money

Vigil Neuroscience (VIGL) IPO set to debut on NASDAQ today.

Also Read: Five bank stocks to explore as rate hike prospects grow

Vigil Neuroscience’s business

Vigil Neuroscience is a microglia-focused therapeutics company. Microglia are the sentinel immune cells in the brain critical for the health of the central nervous system.

It develops treatments for common and rare neurodegenerative diseases by restoring the brain’s sentinel immune cells.

It is headquartered in Cambridge, Massachusetts, with a total staff of 34 as of Nov 30, 2021.

Also Read: Global NFT market topped US$40 billion in 2021: Report

Financials

The company earned no revenue for the nine months ended September 30, 2021 (unaudited results). It had US$110.7 million in cash and cash equivalents as of September 30, 2021.

The net loss was US$30.29 million or US$(19.94) per share diluted (unaudited) for the period.

Also Read: TrumpCoin (TRUMP) gets a thumbs-up on meme contest

Bottomline

Stock markets are volatile. Hence, investors should apply due diligence before investing in shares. Analysts forecast a continued growth momentum for the health sector.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.